Tech Company Financing Transactions
Endocyte Funding Round
Burrill & Company and Sanderling Ventures participated in a $23 million Series C funding round for Endocyte. The funding round was announced by the company on 12/6/2004.
Transaction Overview
Company Name
Announced On
12/6/2004
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series C
Investors
Burrill & Company (Lead Investor)
Proceeds Purpose
This funding will support clinical trials for our receptor-targeted cancer and autoimmune products,
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3000 Kent Ave.
West Lafayette, IN 47906
USA
West Lafayette, IN 47906
USA
Phone
Website
Email Address
Overview
Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Sherman
Chief Financial Officer
Michael Andriole
Chief Medical Officer
Alison Armour
Chief Scientific Officer
Philip Low
Vice President
Iontcho Vlahov
VP - Bus. Development
Matthew Call
VP - Finance
Beth Taylor
VP - Human Resources
Katherine Parker
VP - R & D
Christopher Leamon
Browse more venture capital transactions:
Prev: 12/6/2004: OVATION Pharmaceuticals venture capital transaction
Next: 12/6/2004: Encirq venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs